Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - epatite Ċ, kronika - antivirali għal użu sistemiku - incivo, f'kombinazzjoni ma 'peginterferon alfa u ribavirin, huwa indikat għall-kura tal-ġenotip-1 epatite Ċ kronika f'pazjenti adulti b'mard kumpensat tal-fwied (inkluż ċirrożi):li huma trattament naïve;li jkunu diġà ġew ittrattati b'interferon alfa (pegylated jew mhux pegylated) waħdu jew f'kombinazzjoni ma' ribavirin, inkluż relapsers, dawk li wrew rispons parzjali u dawk li rrispondew null.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - virus tal-ħosba enders' edmonston-razza (ħaj, attenwat), virus tal-gattone jeryl lynn (livell b) razza (ħaj, attenwat), virus tar-rubella wistar ra 27/3-razza (ħaj, attenwat) - rubella; mumps; immunization; measles - vaċċini - m-m-rvaxpro huwa indikat għal tilqim simultanju kontra l-ħożba, il-gattone u r-rubella f'individwi ta ' 12-il xahar jew akbar. għall-użu fil-tifqigħat tal-ħosba, jew għal wara l-espożizzjoni it-tilqim, jew għal użu fi tfal akbar li ma kinux imlaqqma minn 12-il xahar, li huma f'kuntatt ma ' nisa tqal suxxettibbli, u persuni aktarx li jkunu suxxettibbli għall-gattone u r-rubella.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - virus, ħaj attenwat, ħosba, virus, ħaj attenwat, gattone, virus, ħaj attenwat, rubella, virus, ħaj attenwat, varikella - chickenpox; rubella; measles; mumps; immunization - vaċċini - proquad huwa indikat għal tilqim simultanju kontra ħosba, gattone, rubella u varikella f'individwi minn 12-il xahar. proquad jista 'jingħata lill-individwi minn 9 xhur ta' età taħt ċirkostanzi speċjali (e. , li jikkonformaw mal-nazzjonali-iskedi tat-tilqim, tifqigħa is-sitwazzjonijiet, jew jivvjaġġaw lejn ir-reġjun bil-prevalenza għolja tal-ħosba.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dopharma research b.v. - meloxicam - oxicams - pigs; calves - cattlefor-użu fil-infezzjoni respiratorja akuta b'terapija antibijotika xierqa biex jitnaqqsu s-sinjali kliniċi fl-ifrat. għall-użu fid-dijarea flimkien ma 'terapija mill-ġdid ta' reidratazzjoni orali biex jitnaqqsu s-sinjali kliniċi f'għoġġiela ta 'aktar minn ġimgħa ta' età u baqar żgħar li ma jreddgħux. għal terapija aġġuntiva fit-trattament ta 'mastite akuta, flimkien ma' terapija antibijotika. pigsfor-użu fl-noninfectious disturbi lokomotorji biex jitnaqqsu s-sintomi ta'zappip u ta'infjammazzjoni. għall-eżenzjoni ta 'uġigħ wara l-operazzjoni assoċjat ma' kirurġija minuri tat-tessut artab bħal kastrazzjoni. għal terapija aġġuntiva fit-trattament ta 'settiċemija puerperali u toxaemia (sindrome mastite-metritis-agalactia) b'terapija antibijotika xierqa. horsesfor-użu sabiex tittaffa l-infjammazzjoni u serħan mill-uġigħ akut kif ukoll kroniku disturbi muskolu-skeletrali. għall-eżenzjoni ta 'uġigħ assoċjat ma' kolika ekwina.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag  - vardenafil - disfunzjoni erettili - uroloġiċi - trattament ta 'disfunzjoni erettili f'irġiel adulti. id-disfunzjoni erettili hija l-inkapaċità li tinkiseb jew tinżamm erezzjoni tal-pene suffiċjenti għal prestazzjoni sesswali sodisfaċenti. biex levitra ikun effettiv, hija meħtieġa stimulazzjoni sesswali. levitra mhux indikat għall-użu min-nisa.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - neoplażmi fl-istonku - aġenti antineoplastiċi - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulanti, - epatite b kronika: - trattament ta 'pazjenti adulti bl-epatite b kronika assoċjata ma 'evidenza ta' l-epatite b r-replikazzjoni virali (preżenza ta 'hbv-dna u hbeag), livelli elevati ta' alanine aminotransferase (alt) u istoloġikament ippruvat attiva tal-fwied u infjammazzjoni u/jew fibrożi. epatite Ċ kronika:pazjenti adulti:introna huwa ndikat għat-trattament ta ' pazjenti adulti b'epatite Ċ kronika li għandhom transaminases elevati mingħajr dikompensazzjoni tal-fwied u li huma pożittivi għall-hcv-rna jew għall-anti-hcv (ara sezzjoni 4. l-aħjar mod kif tuża introna f'din l-indikazzjoni huwa flimkien ma ' ribavirin. tfal u adolexxenti:introna huwa intenzjonat biex jintuża, f'kors ta 'kombinazzjoni ma' ribavirin, għall-kura ta 'tfal u adolexxenti minn 3 snin' l fuq, li għandhom epatite c kronika, li ma ġietx ikkurata qabel, mingħajr dikumpensazzjoni tal-fwied, u li huma pożittivi għall-hcv-rna. id-deċiżjoni li l-kura għandha tittieħed fuq bażi ta'każ b'każ, filwaqt li jqis l-ebda evidenza ta 'progressjoni tal-marda bħal infjammazzjoni epatika u fibrożi, kif ukoll fatturi oħra ta' pronjożi għar-rispons, il-ġenotip hcv u l-viral load. il-benefiċċju mistenni mill-kura għandu jintiżen kontra l-sigurtà sejbiet dehru għal individwi pedjatriċi fil-provi kliniċi (ara sezzjonijiet 4. 4, 4. 8 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - aġenti antineoplastiċi - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, timolol maleate - glaucoma, open-angle; ocular hypertension - oftalmoloġiċi - tnaqqis fil-pressjoni intraokulari (iop) f'pazjenti adulti bi glawkoma b'angolu miftuħ jew pressjoni għolja fl-għajnejn li għalihom il-monoterapija tipprovdi tnaqqis iop insuffiċjenti.